-
Receipt of EIR from USFDA for inspection conducted at manufacturing facility of Company’s subsidiary Time-Cap Laboratories, Inc.
-
Relonchem Limited receives Marketing Authorization
-
Relonchem Limited receives Marketing Authorization for the product Metformin Hydrochloride 500 mg/ 5ml Oral Solution
-
Press Release - Q4 & FY25 Financial Results
-
Relonchem Limited
receives Marketing Authorization for the product Sennosides 7.5 mg Tablets
-
Relonchem Limited
receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution
-
Approval by Australian TGA for manufacturing of pharmaceutical formulations for Australian markets
-
Marketing Authorization from UK MHRA for Baclofen 10 mg Tablets
-
Marketing Authorization from UKMHRA for Ibuprofen and Paracetamol Film-coated Tablets
-
Q3FY2025 Financial Results
-
USFDA Approval for Loratadine Tablets USP 10 mg
-
Q2&H1FY25 Financial Results
-
Marketing Authorization from UKMHRA for Fluoxetine Capsules
-
Establishment Inspection Report (“EIR”) pursuant to US FDA Inspection
-
Q1FY25 Financial Results
-
Marketing Authorization from UK MHRA
-
Marketing Authorization from UKMHRA
-
Q4FY24 and FY24 Financial Results
-
Marketing Authorisation from UK MHRA for the product Levetiracetam Relonchem 100 mg/mL Oral Solution
-
April 18, 2024 – USFDA Inspection at Company’s manufacturing facility in Verna, Goa, India
-
Q3FY24 Financial Results
-
Q2FY24 Financial Results
-
November 06, 2023 - Marksans Pharma Limited's WOS Relonchem Limited, receives marketing authorisation for Cyanocobalamin 50mg film coated tablets
-
November 03, 2023 - Marksans Pharma Limited's WOS Time-Cap Laboratories, Inc, receives Establishment Inspection Report from US FDA
-
November 01, 2023 - Marksans Pharma Limited undergoes successful inspection from German Health Authorities
-
November 01, 2023 - Marksans Pharma Limited undergoes successful inspection from German Health Authorities
-
October 03, 2023-Marksans Pharma Limited receives US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)
-
Press Release dated 22nd August, 2023 - Marksans Pharma receives USFDA approval for Guaifenesin
-
Press Release – Q1FY24 Financial Results
-
Press Release August 2023
-
Press Release July 2023
-
Press Release - Q4FY23 and FY23 Financial Results
-
Press Release dated 19th April, 2023 - Marksans Pharma completes the acquisition from Tevapharm India, expanding the existing manufacturing capacity in India.
-
Press Release dated 10th March, 2023 - Marksans Pharma Limited announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
-
Press Release - Q3FY23
-
Press Release dated 23rd January, 2023 - Marksans Pharma Limited announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
-
Press Release dated 20th January, 2023 - Marksans Pharma raises Rs. 372.40 crores in equity via conversion of warrants issued to OrbiMed and the Promoter
-
Press Release - Q2FY23
-
Press Release dated 11th October, 2022 - Marksans acquires capacity from Tevapharm India
-
Press release dated 13th August, 2022 – Q1FY23 Financial Results
-
US FDA approval for Pregabalin Capsules, 25 mg, 50 mg,75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg ANDA
-
Press Release dated 21.06.2022
-
Marksans Pharma signs agreement to acquire 100% stake in Dubai-based Access Healthcare for Medical Products L.L.C
-
UK MHRA approval for Bells Healthcare All in One Oral Solution
-
US FDA final approval for Cetirizine Hydrochloride Tablets 5mg and 10mg
-
News Release December 2019
-
News Release September 2019
-
News Release June 2019
-
Receipt of Establishment Inspection Report (EIR) from the US FDA
-
Performance Highlight – Consolidated Q4 2018-19
-
US FDA Audit Update
-
Performance Highlight - Consolidated Q3 2018-19
-
Marksans Pharma Limited announces UK MHRA grant of Marketing Authorisation for Loratadine 5mg / 5ml Oral Solution
-
Performance Highlight – Consolidated for H1 2018-19
-
Performance Highlight – Consolidated Q1 2018-19